- Home
- INSI vs GNFT Comparison
INSI vs GNFT Comparison
Compare INSI & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSI
- GNFT
- Stock Information
- Founded
- INSI 1971
- GNFT 1999
- Country
- INSI United States
- GNFT France
- Employees
- INSI N/A
- GNFT N/A
- Industry
- INSI Investment Managers
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INSI Finance
- GNFT Health Care
- Exchange
- INSI Nasdaq
- GNFT Nasdaq
- Market Cap
- INSI 192.7M
- GNFT 190.6M
- IPO Year
- INSI N/A
- GNFT 2019
- Fundamental
- Price
- INSI $17.06
- GNFT $3.44
- Analyst Decision
- INSI
- GNFT Strong Buy
- Analyst Count
- INSI 0
- GNFT 1
- Target Price
- INSI N/A
- GNFT $13.00
- AVG Volume (30 Days)
- INSI 22.0K
- GNFT 6.5K
- Earning Date
- INSI 01-01-0001
- GNFT 09-19-2024
- Dividend Yield
- INSI 4.90%
- GNFT N/A
- EPS Growth
- INSI N/A
- GNFT N/A
- EPS
- INSI N/A
- GNFT 0.47
- Revenue
- INSI N/A
- GNFT $86,225,222.00
- Revenue This Year
- INSI N/A
- GNFT $145.20
- Revenue Next Year
- INSI N/A
- GNFT N/A
- P/E Ratio
- INSI N/A
- GNFT $7.34
- Revenue Growth
- INSI N/A
- GNFT 175.45
- 52 Week Low
- INSI $14.28
- GNFT $3.31
- 52 Week High
- INSI $16.40
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- INSI 47.55
- GNFT 28.98
- Support Level
- INSI $16.96
- GNFT $3.58
- Resistance Level
- INSI $17.37
- GNFT $3.90
- Average True Range (ATR)
- INSI 0.27
- GNFT 0.14
- MACD
- INSI 0.03
- GNFT 0.02
- Stochastic Oscillator
- INSI 64.77
- GNFT 0.00
About INSI Insight Select Income Fund
Insight Select Income Fund is a diversified closed-end, management investment company. The fund's investment objective is to seek a high rate of return, primarily from interest income and trading activity, from a portfolio principally consisting of debt securities. It offers various solutions such as risk management, liquidity management, and return generation among others.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.